MINI REVIEW article
Sec. Gastrointestinal Cancers
Volume 4 - 2014 | https://doi.org/10.3389/fonc.2014.00035
PIK3CA in colorectal cancer
- Institut für Pathologie, Kantonsspital Baselland, Liestal, Switzerland
PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10–20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of a response to targeted therapy by anti-EGFR monoclonal antibodies. However, these findings have not been confirmed in all studies and subsequent more detailed analysis has revealed that these effects may be restricted to mutations in Exon 20. Finally, mutations in PIK3CA may be the long sought biomarker for successful adjuvant therapy with aspirin in patients with CRC. Therefore, PIK3CA mutations appear to be a promising predictive biomarker; however, further data are needed to conclusively define the impact of somatic mutations in the PIK3CA gene for the management of patients with CRC.
Colorectal cancer (CRC) is the third most common malignancy worldwide, affecting more than 1.2 million patients and leads to over 6,000,000 deaths every year (1). Since the seminal paper by Kinzler and Vogelstein in 1996, it is known that the development of CRC is based on an accumulation of hereditary and somatic genetic alterations ultimately leading to the malignant phenotype (2). The development of CRC through adenomatous precursor lesions has further led to secondary prevention strategy of colonoscopy screening. In addition, a large body of work has finally shown that CRC is not a single disease but a heterogeneous group of neoplasms with a different genetic and epigenetic background. A number of molecular classifications have been suggested and the presence of at least three pathways are generally accepted today, including the chromosomal instability pathway (CIN), the microsatellite instability pathway (MSI), and the epigenetic CpG island methylator phenotype (CIMP) (3). Despite this increasing body of knowledge, the therapeutic options in patients with advanced, metastatic disease remains rather restricted, and the prognosis poor. The introduction of new targeted therapeutics, namely the development of antibodies against the epidermal growth factor receptor (EGFR), has raised new hope for successful treating of advanced CRC (4). However, only a subgroup of patients, especially those with a KRAS wild-type tumor, profit from the anti-EGFR therapy (5). Unfortunately, KRAS wild-type is not sufficient to predict clinical response and mutations in other effectors of the KRAS or KRAS related pathway have been anticipated to be predictive for anti-EGFR response. A promising candidate for this prediction is PIK3CA, which may not only be predictive for targeted therapy by anti-EGFR antibodies but also turned out to be probably a positive biomarker for the neoadjuvant use of aspirin.
Basic Biology of PI3K and PIK3CA
The phosphatidylinositol-3-kinase (PI3K) belongs to a family of heterodimeric lipid kinases consisting of a regulatory and a catalytic subunit, phosphorylating phosphatidylinositol, an important cell membrane element and second messenger involved in cell signaling (6). Activated by various receptor tyrosine kinases, EGFR, human EGFR 2 (HER2), insulin growth factor (IGF-1R), and platelet derived growth factor (PDGFR), the PI3K promotes and regulates various cellular processes, including proliferation, survival, apoptosis, migration, and metabolism (Figure 1). PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), the catalytic p110-alpha subunit of PI3K, has been described to be commonly mutated in various cancer, including glioblastoma, gastric, breast, ovary, lung, and CRC (7, 8). More than 80% of mutations detected in PIK3CA were reported in two hotspots, the helicase domain of exon 9 (codon 542 and 545) and the kinase domain in exon 20 (codon 1047) (8). Downstream effectors of the PI3K pathway include AKT (protein kinase B), a serine–threonine kinase, directly activated by PI3K and the mTOR (mammalian target of rapamycin), another serine–threonine kinase leading to an increased translation of various mRNAs encoding cell cycle regulators, including MYC and cyclin D1 and a potential target of therapeutic inhibition (9). In the PI3K/AKT/mTOR pathway, the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a direct antagonist and mutation or loss of PTEN expression has shown to be correlated with a poor outcome in CRC (10, 11).
Figure 1. Schematic overview of PIK3CA related cell signaling pathways in colorectal cancer. AA, arachidonic acid; AKT, protein kinase B; ERK, extracellular signal-regulated kinase, MEK, MAP kinase kinase; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog deleted on chromosome 10; PGG2, prostaglandin G2; PGH2, prostaglandin H2; PI3K, phosphatidylinositol-3-kinase; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma; RTK, receptor tyrosine kinase.
Frequency and Prognostic Impact of PIK3CA Mutation in Colorectal Cancer
Roughly, PIK3CA mutation has been reported to be present in 10–20% of CRC. Variation in the frequency has been observed in large population based studies compared to clinical studies (12). In addition, as expected, the technique used to evaluate the PIK3CA mutation has a direct impact on the frequency of mutation observed and using pyrosequencing, generally considered a more sensitive assay, shows higher incidence of PIK3CA mutations (15–18%) (13–15) compared to Sanger sequencing (11–12%) (16–18). Mutations are more commonly found in exon 9 compared to exon 20, usually in a ratio of 3:1 to 5:1 and few tumors (<5%) harbor both mutations (19–21). Interestingly, detailed analysis have shown a gradual decrease of PIK3CA mutation from the proximal (cecum/colon ascendens) to the distal (sigma/rectum) site of colon from 21–25% down to 8–9%, respectively (19, 20). Furthermore, PIK3CA mutated CRC has been associated with a mucinous histological phenotype (15, 19, 20). In contrast to other molecular markers, namely BRAF and KRAS, which are mutually exclusive, PIK3CA mutations have shown in the majority of studies to be significantly associated with KRAS mutation and the loss of MGMT (O6-methylguanine-DNA methyltransferase) expression (15, 19, 20). Less consistent or no correlations where reported for CIMP-H, MSI-H, and BRAF mutations (19, 20, 22). In an early study by Ogino and co-workers analyzing patients with curatively resected CRC stage I–III, mutations in PIK3CA were detected in 18% and reported to be associated with a significant worse outcome. This effect, however, was restricted to tumors with wild-type KRAS (14). Similar results were reported in other patient collectives naïve to anti-EGFR therapy with a frequency of PI3KCA mutation ranging from 12 to 13%; but again, this correlation with poor outcome was restricted to KRAS wild-type tumors (16, 23). Further studies, taking in consideration a broader range of molecular markers, did not confirm these previous data for PIK3CA, being an independent prognostic marker for CRC. Mouradov and co-worker analyzed the disease free survival (DFS) in 822 patients with CRC stage II/III and correlated this data with MSI, CIN, and a number of molecular biomarkers, including PIK3CA (18). In this study, only CIN and MSI were associated with DFS but with none of the molecular biomarkers, including PIK3CA (18). Similarly, in a Scandinavian evaluation, analyzing two study cohorts of 611 patients, PIK3CA did not show any prognostic impact (24). In this study, however, the molecular analysis of PIK3CA was restricted to exon 20, leading to the expected low frequency of 2.2% PIK3CA mutated tumors. The rationale behind this approach is that some studies have suggested that the poor prognosis of PIK3CA is restricted to exon 20 mutations and that the analysis of exon 9 may produce false positive results due to presence of pseudogenes (25, 26). Indeed, in breast cancer, the prognostic impact of PIK3CA has been similarly reported to be restricted to exon 20 (27, 28). This concept is supported by in vitro studies showing that mutations in the helical (exon 9) and kinase (exon 20) domain use different and independent mechanisms for cell transformation (29). In addition, the effect of PIK3CA mutation is RAS dependent in the helical but not the kinase domain, which may explain the stronger association of KRAS mutation with exon 9 mutations of PIK3C (19, 22). Taken together, mutation of PIK3CA in CRC may have a slight prognostic impact in anti-EGFR naïve patients; the extent, if present, of this impact, however, especially in respect to different mutations, remains to be clarified.
PIK3CA as Predictive Marker in Anti-EGFR Therapy
Despite the fact that CRC can curably be treated at early stages, advanced tumors, namely metastatic cancer are associated with a high mortality rate and a 5-year survival of below 10% (30). The introduction of a targeted therapy using monoclonal anti-EGFR antibody, namely panitumumab and cetuximab, in combination chemotherapy or as a single agent, has added a further promising treatment option (4, 31). However, only a subgroup of patients, usually <10% in unselected patients, profit of anti-EGFR antibody treatment (5, 32). Several clinical trials have shown that RAS mutations are the most important negative predictive factor in CRC, primarily mutations in exon 1 and 2 of RAS, but, as recently been shown, also of exon 3 and 4 of KRAS and NRAS, respectively (32, 33). However, even in wild-type RAS tumors, 50–60% of patients do not profit from an anti-EGFR therapy. Based on the well-established pathway of the EGFR receptor, other downstream elements of the direct or associated signaling pathway, including BRAF/MEK/ERK and PIK3/PTEN/AKT/mTOR have been analyzed as potential biomarker (Figure 1). In a first study, analyzing 110 patients with CRC, Sartore-Bianchi and co-workers reported a significant resistance to EGFR-targeted therapy in the 13.6% of PIK3CA mutated cancers (34). The predictive value of PIK3CA mutation in RAS wild-type CRC was supported subsequent by additional studies (35, 36). Interestingly, however, in a study by Prenen and co-workers analyzing 200 chemorefractory patients treated with cetuximab, PIK3CA mutation, detected in 11.5% of tumors, was no predictor of anti-EGFR response (37). Further detailed studies, analyzing PIK3CA mutation of exon 9 and exon 20 separately, may possibly give the explanation for the discrepancy of the predictive value of PIK3CA as a biomarker for anti-EGFR response. In a carefully performed, retrospective study including 743 CRC, de Roock and co-workers describe in KRAS wild-type tumors a significant association of objective response, overall survival, and progression free survival in exon 20 but not in exon 9 mutated tumors (22). As expected, the incidence of exon 20 mutation in PIK3CA was low, i.e., 3.0%, however, the mutation analysis added another 1.3% improvement of anti-EGFR response prediction, similar to the improvement of prediction by testing NRAS (i.e., 1.5%) (22).
PIK3CA as Biomarker for Adjuvant Aspirin Therapy
Based on several observational studies as well as randomized trials, it has been long considered that aspirin is efficient in preventing colorectal adenomas and cancers (38, 39). This anti-tumor effect is thought to be driven by the inhibition of cyclooxygenases [COX-2, officially called HGNC:9605 or PTGS2 (prostaglandin-endoperoxide synthase 2)], interacting with the arachidonic acid metabolite pathway, however, the detailed mechanism of action is not completely understood [reviewed in Ref. (40)]. This anti-tumor effect has reported to be restricted to patients with cancers showing an over expression of COX-2 demonstrated by immunohistochemistry (41). However, as 60–85% of CRCs has been reported to over express COX-2 (42), immunohistochemistry is considered a less reliable predictive marker for adjuvant aspirin therapy. Due to its side effects, namely gastrointestinal irritation and bleeding, wide spread and unselected chemoprevention by aspirin is not recommended. In addition, more specific COX-2 inhibitors, such as rofecoxib or celecoxib, had to be withdrawn from the market due to their cardiovascular side effects. Therefore, the recent study by Liau and co-workers, reporting an improved survival of CRC patients using regular aspirin in tumors harboring a PIK3CA mutation, has created a lot of interest (13). Using data of two large prospective studies, the Nurses’ Health study and the Health Professionals Follow-up Study, the authors were able to follow 964 patients for a median follow-up time of 153 months. PIK3CA mutations were detected in 16.7% of tumors, and in the patients with mutated cancer, the regular use of aspirin was associated with a reduction of tumor specific and over all mortality of 82 and 46%, respectively. The precise molecular and biological mechanisms of aspirin to the PIK3/AKT/mTOR pathway have to be clarified in detail (Figure 1). In vitro studies indicate that the PIK3CA induces the expression of COX-2 (43). In addition, COX unrelated effects, namely the change of the microenvironment and subsequently the intestinal microbioma in the gut as well as the anti-thrombotic effect of aspirin, which may be relevant in the development of metastasis, have to be considered (44, 45). An additional clinical study by Domingo and co-workers, again retrospectively analyzing a large prospective study cohort of 896 patients with CRC, the patients of the VICTOR trial, has confirmed the predictive value of PIK3CA mutation for taking aspirin in an adjuvant setting (46). Interestingly, however, this effect could not be observed in patients taken the specific COX-2 inhibitor rofecoxib. These data indicate that the predictive value of PIK3CA mutation goes beyond COX-2 inhibition and underlies the importance of a COX-independent effect of aspirin in the prevention of cancer development and spread. Despite the promising results reported by these two studies, there is some caveat to express: based on the stratification necessary, i.e., patients with PIK3CA mutated tumors and taking regularly aspirin, the numbers of patients is relatively small in both studies (60 and 45 patients, respectively) and prospective, large scale clinical trials are needed to confirm this data, highly relevant for the future management of patients with CRC.
In conclusion, somatic mutations of PIK3CA are present in 10–20% of CRC, basically confined to exon 9 and exon 20 (or more precisely, these are the exons usually analyzed). The majority of studies are based on pooled data in respect to the exon mutated, but experimental as well as epidemiological evidence point in the direction that mutation in exon 20 but not in exon 9 may be biologically relevant. So far, mutation of PIK3CA as a single prognostic marker seems to have, if some, a minor effect of the overall prognosis of CRC but a small and distinct predictive impact for anti-EGFR therapy in RAS wild-type tumors. In addition, there is strong evidence of the predictive value of PIK3CA mutations for adjuvant therapy using aspirin, however, further data are needed to definitively define the impact of, especially exon specific, PIK3CA mutation in the management of patients with CRC.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893–917. doi: 10.1002/ijc.25516
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell (1996) 87:159–70. doi:10.1016/S0092-8674(00)81333-1
3. Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, et al. Individualized therapy for metastatic colorectal cancer. J Intern Med (2013) 274:1–24. doi:10.1111/joim.12070
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 360:1408–17. doi:10.1056/NEJMoa0805019
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 26:1626–34. doi:10.1200/JCO.2007.14.7116
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 2:489–501. doi:10.1038/nrc839
7. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 64:7678–81. doi:10.1158/0008-5472.CAN-04-2933
8. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304:554. doi:10.1126/science.1096502
9. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 9:550–62. doi:10.1038/nrc2664
10. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology (2010) 56:229–39. doi:10.1111/j.1365-2559.2009.03468.x
11. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol (2008) 8:56. doi:10.1186/1471-230X-8-56
12. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013). doi:10.1038/onc.2013.244
13. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 367:1596–606. doi:10.1056/NEJMoa1207756
14. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 27:1477–84. doi:10.1200/JCO.2008.18.6544
15. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 10:534–41. doi:10.1593/neo.08336
16. Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, Kobayashi H, et al. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett (2012) 3:565–70. doi:10.3892/ol.2011.544
17. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta (2012) 413:1605–11. doi:10.1016/j.cca.2012.04.029
18. Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 108:1785–93. doi:10.1038/ajg.2013.292
19. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One (2013) 8:e65479. doi:10.1371/journal.pone.0065479
20. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res (2013) 19:3285–96. doi:10.1158/1078-0432.CCR-12-3614
21. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 18:2257–68. doi:10.1158/1078-0432.CCR-11-2410
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 11:753–62. doi:10.1016/S1470-2045(10)70130-3
23. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis (2013) 28:1637–42. doi:10.1007/s00384-013-1715-8
24. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 108:2153–63. doi:10.1038/bjc.2013.212
25. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) (2011) 34:523–31. doi:10.1007/s13402-011-0054-4
26. Muller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res (2007) 31:27–32. doi:10.1016/j.leukres.2006.04.011
27. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol (2008) 15:1064–9. doi:10.1245/s10434-007-9751-7
28. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 15:5049–59. doi:10.1158/1078-0432.CCR-09-0632
29. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 105:2652–7. doi:10.1073/pnas.0712169105
30. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 23:8664–70. doi:10.1200/JCO.2005.01.6071
31. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 351:337–45. doi:10.1056/NEJMoa033025
32. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol (2009) 27:2091–6. doi:10.1200/JCO.2009.21.9170
33. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 369:1023–34. doi:10.1056/NEJMoa1305275
34. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 69:1851–7. doi:10.1158/0008-5472.CAN-08-2466
35. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2009) 20:84–90. doi:10.1093/annonc/mdn541
36. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 11:143–50. doi:10.1016/j.clcc.2011.12.001
37. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 15:3184–8. doi:10.1158/1078-0432.CCR-08-2961
38. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 348:891–9. doi:10.1056/NEJMoa021735
39. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 376:1741–50. doi:10.1016/S0140-6736(10)61543-7
40. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 9:259–67. doi:10.1038/nrclinonc.2011.199
41. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 302:649–58. doi:10.1001/jama.2009.1112
42. Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One (2013) 8:e58891. doi:10.1371/journal.pone.0058891
43. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene (2000) 19:5517–24. doi:10.1038/sj.onc.1203952
44. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol (2012) 10:575–82. doi:10.1038/nrmicro2819
45. Gil-Bernabe AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol (2013) 162:433–41. doi:10.1111/bjh.12381
46. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 31:4297–305. doi:10.1200/JCO.2013.50.0322
Keywords: biomarker, colorectal cancer, PIK3CA, prognosis, prediction, aspirin, adjuvant therapy, EGFR
Citation: Cathomas G (2014) PIK3CA in colorectal cancer. Front. Oncol. 4:35. doi: 10.3389/fonc.2014.00035
Received: 30 December 2013; Paper pending published: 23 January 2014;
Accepted: 12 February 2014; Published online: 03 March 2014.
Edited by:Inti Zlobec, University of Bern, Switzerland
Reviewed by:Inti Zlobec, University of Bern, Switzerland
Qianghua Xia, The Children’s Hospital of Philadelphia, USA
Copyright: © 2014 Cathomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gieri Cathomas, Institut für Pathologie, Kantonsspital Baselland, Mühlemattstrasse 11, Liestal CH-4410, Switzerland e-mail: firstname.lastname@example.org